weight loss drugs non glp 1 Chart: in 8 Americans Now Use GLP-1 for GLP-1 Medications: Everything You Need

An androgen receptor N-terminal domain antagonist for treating prostate cancer

It isn't just about how much of an ingredient you get

The bottom line: Our findings suggest that GLP-1RA and SGLT2i (and especially SGLT2i with the lowest number needed to treat (NNT) for nearly all study outcomes) may be the preferred glucose-lowering agents for cardiovascular risk reduction in patients at moderate risk for CVD, building on and consistent with existing RCT evidence in the high-risk population. This report highlights potential preference for GLP-1 drugs as a first-line treatment for Type 2 diabetes related to its cardioprotective effect

2021;13:e12253